NOVARTIS

Appendix to
Lumiracoxib (COX189) Background Document for Novartis Presentation to FDA Advisory Committee
(February 16-18, 2005)

Errata: Comparison of document released on January 13, 2005 with the updated version released on February 3, 2005

Document status:	Final
Release date:	February 10, 2005
Number of pages:	15

AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION

Page 8

Change: Novartis has performed a standard and cumulative meta-analysis of the cardiovascular safety of lumiracoxib for all doses, including supratherapeutic doses (100 mg to 1200mg od), of all completed randomized controlled trials of lumiracoxib ≥ 1 week duration.

To: Novartis has performed a standard and cumulative meta-analysis of the cardiovascular safety of lumiracoxib for all doses, including supratherapeutic doses (100 mg to 1200mg od), of all randomized controlled trials of lumiracoxib ≥ 1 week duration **completed by December 31, 2004**.

Change: (44 patient – years compared with 9796 patient-years for patients taking lumiracoxib for treatment of the signs and symptoms of either osteoarthritis or rheumatoid arthritis)

To: (44 patient – years compared with **9797** patient-years for patients taking lumiracoxib for treatment of the signs and symptoms of either osteoarthritis or rheumatoid arthritis

Page 12

Change: A total of 33,933 patients were included in the safety population used for the analyses; of these, 17339 patients (9796.4 patient-years exposure) were randomized to lumiracoxib and 16594 patients were allocated to controls (8824.5 patient-years exposure). Prospective adjudication for the components of Antiplatelet Trialist's Collaboration (APTC) endpoint occurred for 15,678.7 of the total 18,620.9 patient-years exposure. … Four trials continued for one year (TARGET, and trials 112, 2335, and 2361 with their extensions) totaling 22,781 safety patients (16,526.1 patient-years exposure).

To: A total of 33,933 patients were included in the safety population **from these trials ~~used for the analyses~~**; of these, 17339 patients (**9797** patient-years exposure) were randomized to lumiracoxib and 16594 patients were allocated to controls (**8824.6** patient-years exposure). Prospective adjudication for the components of Antiplatelet Trialist's Collaboration (APTC) endpoint occurred for **15,679.3** of the total **18,621.6** patient-years exposure. … Four trials continued for one year (TARGET, and trials 112, 2335, and 2361 with their extensions) totaling 22,781 safety patients (**16,526.7** patient-years exposure).

Page 13

Change: **Table 1-2 Relative risk of APTC endpoint with lumiracoxib and comparators from a stratified meta-analysis**

Comparisons	Contrasts	Risk ratio	95% CI for risk ratio	Interaction p-value
All comparators	all Lumiracoxib - all control	1.14	(0.83,1.57)	
Type of control	Lumiracoxib - placebo	0.88	(0.34,2.25)	0.6172
	Lumiracoxib - Non Naproxen NSAID	0.83	(0.46,1.51)	
	Lumiracoxib - Naproxen	1.49	(0.94,2.36)	
Duration	>3 months: Lumiracoxib - control	1.18	(0.84,1.67)	0.6121
	<=3 months: Lumiracoxib - control	0.93	(0.38,2.29)	
External Adjudication	external: Lumiracoxib - control	1.08	(0.75,1.54)	0.5562
	no external: Lumiracoxib - control	1.36	(0.66,2.80)	
Dose*	Lumiracoxib high dose -control	1.17	(0.84,1.65)	0.5379
	Lumiracoxib low dose -control	0.99	(0.57,1.71)	

To:

Comparisons	Contrasts	Risk ratio	95% CI for risk ratio	Interaction p-value
All comparators	all Lumiracoxib -all control	**1.12**	**(0.82,1.55)**	
Type of control	Lumiracoxib - placebo	**1.08**	**(0.41,2.86)**	**0.9102**
	Lumiracoxib - non-naproxen NSAID	0.83	(0.46,1.51)	
	Lumiracoxib - Naproxen	1.49	(0.94,2.36)	
Indication	**RA: Lumiracoxib - control**	**1.59**	**(0.61,4.13)**	**0.4360**
	OA: Lumiracoxib - control	**1.08**	**(0.77,1.51)**	
Duration	>3 months: Lumiracoxib - control	**1.15**	**(0.82,1.61)**	**0.8162**
	<=3 months: Lumiracoxib - control	**1.02**	**(0.41,2.57)**	
External Adjudication	external: Lumiracoxib - control	**1.06**	**(0.74,1.51)**	**0.5274**
	no external: Lumiracoxib - control	**1.36**	**(0.66,2.80)**	
Dose	Lumiracoxib high dose -control	**1.15**	**(0.82,1.61)**	**0.5506**
	Lumiracoxib low dose -control	**0.98**	**(0.57,1.69)**	

Change: **Table 1-3 Relative risk of MI with lumiracoxib and comparators from a stratified meta-analysis**

Comparisons	Contrasts	Risk ratio	95% CI for risk ratio	Interaction p-value
All comparators	all Lumiracoxib -all control	1.28	(0.78, 2.12)	
Type of control	Lumiracoxib - placebo	1.06	(0.20, 6.69)	0.7484
	Lumiracoxib - Non Naproxen NSAID	0.80	(0.28, 2.25)	
	Lumiracoxib - Naproxen	1.69	(0.82, 3.48)	
Duration	>3 months: Lumiracoxib - control	1.30	(0.75, 2.27)	0.9191
	<=3 months: Lumiracoxib - control	1.39	(0.41, 4.72)	
External Adjudication	external: Lumiracoxib - control	1.20	(0.67, 2.16)	0.7152
	no external: Lumiracoxib - control	1.48	(0.54, 4.05)	
Dose	Lumiracoxib high dose -control	1.34	(0.79, 2.29)	0.5799
	Lumiracoxib low dose -control	1.07	(0.46, 2.49)	

To:

Comparisons	Contrasts	Risk ratio	95% CI for risk ratio	Interaction p-value
All comparators	all Lumiracoxib -all control	1.28	(0.78,2.12)	
Type of control	Lumiracoxib - placebo	**1.27**	**(0.25,6.56)**	**0.9010**
	Lumiracoxib - non-naproxen NSAID	0.80	(0.28,2.25)	
	Lumiracoxib - Naproxen	1.69	(0.82,3.48)	
Indication	**RA: Lumiracoxib - control**	**2.32**	**(0.43,12.4)**	**0.4407**
	OA: Lumiracoxib - control	**1.20**	**(0.71,2.05)**	
Duration	>3 months: Lumiracoxib - control	1.30	(0.75,2.27)	**0.9189**
	<=3 months: Lumiracoxib - control	1.39	(0.41,4.72)	
External Adjudication	external: Lumiracoxib - control	1.20	(0.67,2.16)	**0.7151**
	no external: Lumiracoxib - control	1.48	(0.54,4.05)	
Dose	Lumiracoxib high dose -control	1.34	(0.79,2.29)	**0.5859**
	Lumiracoxib low dose -control	1.07	(0.46,**2.50**)	

Page 14

Change: The cumulative meta-analysis analyzed more than 34 000 patients with a total of 161 APTC events including 66 myocardial infarctions.

To: The cumulative meta-analysis analyzed more than 34 000 patients with a total of **162** APTC events including 66 myocardial infarctions.

Page 15

Change: **Figure 1-1 Cumulative stratified meta-analysis of APTC events in randomized trials comparing lumiracoxib with controls**

Year	Cumulative patients	Cumulative events	RR	95%CI
2001	3772	2	1.38	0.08 to 24.95
	4814	5	0.69	0.11 to 4.41
	4934	6	0.95	0.18 to 5.01
	6173	8	0.55	0.13 to 2.44
2002	6684	12	0.51	0.15 to 1.78
	8284	14	0.72	0.24 to 2.17
	9348	27	1.12	0.50 to 2.48
	9942	27	1.03	0.47 to 2.27
	11066	34	1.36	0.66 to 2.79
2003	11474	34	1.36	0.66 to 2.79
	12625	36	1.37	0.68 to 2.75
2004	30869	145	1.20	0.86 to 1.68
	32553	150	1.18	0.84 to 1.64
	34104	152	1.17	0.84 to 1.63
	34362	157	1.14	0.83 to 1.58
	34668	161	1.14	0.83 to 1.57



To:

Year	Cumulative patients	Cumulative events	RR	95%CI
2001	3772	4	0.90	0.12 to 7.05
	4814	7	0.65	0.14 to 3.07
	4934	8	0.85	0.20 to 3.56
	6173	10	0.57	0.15 to 2.10
2002	6684	14	0.52	0.17 to 1.63
	8284	16	0.70	0.25 to 1.95
	9348	27	1.04	0.47 to 2.28
	9942	27	1.03	0.47 to 2.27
	11066	34	1.36	0.66 to 2.79
2003	11474	34	1.36	0.66 to 2.79
	12625	36	1.37	0.68 to 2.75
2004	30869	145	1.20	0.86 to 1.68
	32553	149	1.19	0.86 to 1.66
	34104	151	1.19	0.86 to 1.66
	34362	156	1.16	0.84 to 1.60
	34668	162	1.12	0.82 to 1.55



Page 15

Change: **Figure 1-2 Cumulative stratified meta-analysis of MI in randomized trials comparing lumiracoxib with controls**

Year	Cumulative patients	Cumulative events	RR	95%CI
2001	3772	2	1.38	0.08 to 24.95
	4814	4	1.07	0.14 to 8.21
	4934	5	1.45	0.22 to 9.33
	6173	5	1.48	0.23 to 9.53
2002	6684	7	0.78	0.17 to 3.71
	8284	9	1.19	0.30 to 4.66
	9348	17	1.40	0.50 to 3.93
	9942	17	1.30	0.47 to 3.61
	11066	18	1.48	0.54 to 4.04
2003	11474	18	1.48	0.54 to 4.05
	12625	19	1.68	0.62 to 4.53
2004	30869	59	1.42	0.83 to 2.44
	32553	60	1.37	0.81 to 2.33
	34104	60	1.37	0.81 to 2.33
	34362	63	1.29	0.77 to 2.16
	34668	66	1.28	0.78 to 2.12



To:

Year	Cumulative patients	Cumulative events	RR	95%CI
2001	3772	4	0.90	0.12 to 7.05
	4814	6	0.87	0.16 to 4.60
	4934	7	1.13	0.24 to 5.35
	6173	7	1.18	0.25 to 5.54
2002	6684	9	0.75	0.19 to 2.95
	8284	11	1.06	0.31 to 3.63
	9348	17	1.31	0.47 to 3.63
	9942	17	1.30	0.47 to 3.61
	11066	18	1.48	0.54 to 4.04
2003	11474	18	1.48	0.54 to 4.05
	12625	19	1.68	0.62 to 4.53
2004	30869	59	1.42	0.83 to 2.44
	32553	60	1.37	0.81 to 2.33
	34104	60	1.37	0.81 to 2.33
	34362	63	1.29	0.77 to 2.16
	34668	66	1.28	0.78 to 2.12



Page 16

Change: When the analysis was done excluding naproxen, the risk decreased to 1.09 (95 % CI 0.56 – 2.12) which supports our assertion that naproxen at the high dose of 500 mg bid may have a antithrombotic effect (Figure 1-3 below)

To: When **~~the analysis was done excluding naproxen~~ a stratified meta-analysis was performed comparing lumiracoxib to non-naproxen comparators**, the risk decreased to **1.01** (95 % CI 0.**50 – 2.02**) which supports our assertion that naproxen at the high dose of 500 mg bid may have **an** antithrombotic effect (Figure 1-3 below)

Change: **Figure 1-3 Cumulative meta-analysis of MI in randomized trials comparing lumiracoxib with non-naproxen NSAIDs**

Evaluation	Cumulative patients	Cumulative events	RR	95%CI
1	3772	2	1.38	0.08 to 24.95
2	4814	4	1.07	0.14 to 8.21
3	4893	5	1.25	0.18 to 8.61
4	6132	5	1.27	0.18 to 8.81
5	6643	7	0.69	0.14 to 3.48
6	8243	9	1.12	0.28 to 4.47
7	9307	17	1.38	0.49 to 3.87
8	9901	17	1.30	0.47 to 3.60
9	10746	18	1.35	0.49 to 3.67
10	11154	18	1.35	0.49 to 3.68
11	12077	19	1.48	0.55 to 3.99
12	25591	49	1.11	0.54 to 2.28
13	27275	50	1.06	0.53 to 2.13
14	28826	50	1.08	0.54 to 2.17
15	28951	51	1.08	0.54 to 2.16
16	29257	54	1.09	0.56 to 2.12



To: **Figure 1-3 Cumulative meta-analysis of MI in randomized trials comparing lumiracoxib versus all non-naproxen comparators**

Year	Cumulative patients	Cumulative events	RR	95%CI
2001	3772	4	0.90	0.12 to 7.05
	4814	6	0.87	0.16 to 4.60
	6053	6	0.91	0.17 to 4.80
2002	6564	8	0.58	0.13 to 2.54
	8164	10	0.88	0.24 to 3.19
	9228	16	1.19	0.42 to 3.37
	9822	16	1.18	0.42 to 3.34
	10667	17	1.24	0.45 to 3.43
2003	11075	17	1.24	0.45 to 3.43
	11998	18	1.37	0.50 to 3.74
2004	20771	30	1.06	0.50 to 2.22
	22455	31	0.99	0.48 to 2.05
	24006	31	1.00	0.48 to 2.06
	24312	34	1.01	0.50 to 2.02



Change: **Table 1-4 Relative risk of stroke with lumiracoxib and comparators from a stratified meta-analysis**

Comparisons	Contrasts	Risk ratio	95% CI for risk ratio	Interaction p-value
All comparators	all Lumiracoxib - all control	1.20	(0.70, 2.07)	
Type of control	Lumiracoxib - placebo	0.89	(0.15, 5.08)	0.3174
	Lumiracoxib - Non Naproxen NSAID	0.91	(0.35, 2.35)	
	Lumiracoxib - Naproxen	1.46	(0.70, 3.07)	
Duration	>3 months: Lumiracoxib - control	1.18	(0.68, 2.06)	
	<=3 months: Lumiracoxib - control		not estimable	
External Adjudication	external: Lumiracoxib - control	1.06	(0.59, 1.88)	0.1424
	no external: Lumiracoxib - control	4.44	(0.51, 38.9)	
Dose	Lumiracoxib high dose - control	1.19	(0.67, 2.11)	0.8955
	Lumiracoxib low dose - control	1.12	(0.43, 2.92)	

To:

Comparisons	Contrasts	Risk ratio	95% CI for risk ratio	Interaction p-value
All comparators	all Lumiracoxib -all control	**1.02**	**(0.61,1.71)**	
Type of control	Lumiracoxib - placebo	**0.59**	**(0.13,2.74)**	**0.8603**
	Lumiracoxib - non-naproxen NSAID	0.91	(0.35,2.35)	
	Lumiracoxib - Naproxen	**1.42**	**(0.70,2.91)**	
Indication	**RA: Lumiracoxib - control**	**2.32**	**(0.43,12.4)**	**0.2793**
	OA: Lumiracoxib - control	**0.93**	**(0.54,1.60)**	
Duration	>3 months: Lumiracoxib - control	**1.08**	**(0.64,1.84)**	**0.3445**
	<=3 months: Lumiracoxib - control	**0.38**	**(0.04,3.84)**	
External Adjudication	external: Lumiracoxib - control	**0.97**	**(0.56,1.68)**	**0.5705**
	no external: Lumiracoxib - control	**1.48**	**(0.36,6.13)**	
Dose	Lumiracoxib high dose -control	**1.01**	**(0.59,1.75)**	**0.9928**
	Lumiracoxib low dose -control	**1.02**	**(0.42,2.45)**	

Page 17

Change: **Figure 1-4 Cumulative stratified meta-analysis of stroke in randomized trials comparing lumiracoxib with controls**

Year	Cumulative patients	Cumulative events	RR	95%CI
2003	11474	7	4.77	0.54 to 42.00
	12625	7	4.92	0.56 to 43.29
2004	30869	52	1.26	0.72 to 2.22
	32553	55	1.20	0.69 to 2.06
	34104	55	1.19	0.69 to 2.06
	34362	55	1.19	0.69 to 2.06
	34668	56	1.20	0.70 to 2.07



To:

Year	Cumulative patients	Cumulative events	RR	95%CI
2002	9348	5	1.07	0.17 to 6.71
	9942	5	1.07	0.17 to 6.66
	11066	9	1.56	0.37 to 6.51
2003	11474	9	1.56	0.37 to 6.51
	12625	10	1.21	0.33 to 4.46
2004	30869	55	1.11	0.64 to 1.91
	32553	57	1.10	0.65 to 1.88
	34104	58	1.06	0.63 to 1.80
	34362	59	1.09	0.65 to 1.84
	34668	62	1.02	0.61 to 1.71



Page 18

Change: **Table 1-5 Relative risk of peripheral vascular event with lumiracoxib and comparators from a stratified meta-analysis**

Comparisons	Contrasts	Risk ratio	95% CI for risk ratio	Interaction p-value
All comparators	all Lumiracoxib -all control	1.10	(0.56, 2.16)	
Type of control	Lumiracoxib - placebo	0.99	(0.25, 3.97)	0.1631
	Lumiracoxib - Non Naproxen NSAID	1.82	(0.44, 7.53)	
	Lumiracoxib - Naproxen	0.79	(0.26, 2.42)	
Duration	>3 months: Lumiracoxib - control	1.36	(0.62, 2.95)	0.3967
	<=3 months: Lumiracoxib - control	0.68	(0.16, 2.95)	
External Adjudication	external: Lumiracoxib - control	1.01	(0.45, 2.26)	0.7378
	no external: Lumiracoxib - control	1.30	(0.37, 4.57)	
Dose	Lumiracoxib high dose - control	0.98	(0.46, 2.09)	0.3570
	Lumiracoxib low dose - control	1.55	(0.61, 3.95)	

To:

Comparisons	Contrasts	Risk ratio	95% CI for risk ratio	Interaction p-value
All comparators	all Lumiracoxib -all control	**0.98**	**(0.51,1.89)**	
Type of control	Lumiracoxib - placebo	**0.74**	**(0.21,2.61)**	**0.1086**
	Lumiracoxib - non-naproxen NSAID	1.82	(0.44,7.53)	
	Lumiracoxib - Naproxen	**0.69**	**(0.23,2.05)**	
Indication	**RA: Lumiracoxib - control**	**0.93**	**(0.22,3.84)**	**0.8982**
	OA: Lumiracoxib - control	**1.03**	**(0.49,2.14)**	
Duration	>3 months: Lumiracoxib - control	**1.15**	**(0.55,2.41)**	**0.5175**
	<=3 months: Lumiracoxib - control	0.68	(0.16,2.95)	
External Adjudication	external: Lumiracoxib - control	**0.87**	**(0.40,1.88)**	**0.5815**
	no external: Lumiracoxib - control	1.30	(0.37,4.57)	
Dose	Lumiracoxib high dose -control	**0.89**	**(0.43,1.86)**	**0.3986**
	Lumiracoxib low dose -control	**1.35**	**(0.54,3.38)**	

Page 18

Change: **Figure 1-5 Cumulative stratified meta-analysis of peripheral vascular events in randomized trials comparing lumiracoxib with controls**

Year	Cumulative patients	Cumulative events	RR	95%CI
2001	4814	3	1.56	0.13 to 18.31
	4934	3	1.56	0.13 to 18.25
	6173	7	1.10	0.24 to 5.08
2002	6684	7	1.16	0.25 to 5.37
	8284	7	1.14	0.24 to 5.30
	9348	9	1.29	0.36 to 4.57
	9942	9	0.93	0.24 to 3.59
	11066	11	1.33	0.38 to 4.72
2003	11474	11	1.33	0.38 to 4.72
	12625	11	1.38	0.39 to 4.90
2004	30869	31	1.10	0.53 to 2.27
	32553	32	1.03	0.50 to 2.10
	34104	34	1.02	0.51 to 2.04
	34362	34	1.02	0.51 to 2.03
	34668	36	1.10	0.56 to 2.16



To:

Year	Cumulative patients	Cumulative events	RR	95%CI
2001	4814	3	1.56	0.13 to 18.31
	4934	3	1.56	0.13 to 18.25
	6173	6	1.64	0.29 to 9.36
2002	6684	6	1.73	0.30 to 9.87
	8284	6	1.66	0.29 to 9.49
	9348	8	1.19	0.27 to 5.17
	9942	8	1.18	0.27 to 5.13
	11066	11	1.30	0.37 to 4.56
2003	11474	11	1.30	0.37 to 4.57
	12625	12	1.08	0.33 to 3.52
2004	30869	32	1.03	0.51 to 2.10
	32553	33	0.97	0.48 to 1.95
	34104	35	0.96	0.49 to 1.90
	34362	36	0.91	0.48 to 1.77
	34668	38	0.98	0.51 to 1.89



Page 19

Change: **Table 1-8 Relative risk for MI / all strokes / peripheral vascular events – combined, with lumiracoxib and comparators from a stratified meta-analysis**

Comparisons	Contrasts	Risk ratio	95% CI for risk ratio	Interaction p-value
All comparators	all Lumiracoxib -all control	1.24	(0.89, 1.71)	
Type of control	Lumiracoxib - placebo	0.97	(0.39, 2.41)	0.5519
	Lumiracoxib - Non Naproxen NSAID	1.05	(0.56, 1.98)	
	Lumiracoxib - Naproxen	1.40	(0.88, 2.23)	
Duration	>3 months: Lumiracoxib - control	1.29	(0.9, 1.83)	0.6445
	<=3 months: Lumiracoxib - control	1.04	(0.43,2.50)	
External Adjudication	external: Lumiracoxib - control	1.12	(0.78, 1.62)	0.3034
	no external: Lumiracoxib - control	1.69	(0.82, 3.50)	
Dose	Lumiracoxib high dose -control	1.22	(0.86, 1.73)	0.9485
	Lumiracoxib low dose -control	1.24	(0.73, 2.11)	

To: **Table 1-6 Relative risk for MI / all strokes / peripheral vascular events – combined, with lumiracoxib and comparators from a stratified meta-analysis**

Comparisons	Contrasts	Risk ratio	95% CI for risk ratio	Interaction p-value
All comparators	all Lumiracoxib -all control	**1.13**	**(0.82,1.54)**	
Type of control	Lumiracoxib - placebo	**0.80**	**(0.35,1.84)**	**0.4585**
	Lumiracoxib - non-naproxen NSAID	1.05	(0.56,1.98)	
	Lumiracoxib - Naproxen	**1.34**	**(0.85,2.12)**	
Indication	**RA: Lumiracoxib - control**	**1.62**	**(0.67,3.95)**	**0.3769**
	OA: Lumiracoxib - control	**1.07**	**(0.77,1.50)**	
Duration	>3 months: Lumiracoxib - control	**1.19**	**(0.84,1.67)**	**0.5184**
	<=3 months: Lumiracoxib - control	**0.89**	**(0.38,2.07)**	
External Adjudication	external: Lumiracoxib - control	**1.04**	**(0.73,1.49)**	**0.4004**
	no external: Lumiracoxib - control	**1.44**	**(0.72,2.86)**	
Dose	Lumiracoxib high dose -control	**1.12**	**(0.80,1.58)**	**0.9647**
	Lumiracoxib low dose -control	**1.14**	**(0.68,1.90)**	

Change: **Figure 1-6 Cumulative stratified meta-analysis for MI / all strokes / peripheral vascular events – combined, in randomized trials comparing lumiracoxib with controls**

Year	Cumulative patients	Cumulative events	RR	95%CI
2001	3772	4	2.85	0.27 to 30.26
	4814	7	1.17	0.25 to 5.56
	4934	8	1.43	0.32 to 6.30
	6173	12	1.21	0.37 to 3.97
2002	6684	14	0.87	0.30 to 2.54
	8284	16	1.06	0.39 to 2.93
	9348	29	1.51	0.70 to 3.26
	9942	29	1.35	0.62 to 2.96
	11066	36	1.68	0.81 to 3.48
2003	11474	36	1.68	0.81 to 3.48
	12625	37	1.83	0.89 to 3.77
2004	30869	141	1.32	0.93 to 1.86
	32553	146	1.25	0.89 to 1.75
	34104	148	1.24	0.89 to 1.74
	34362	151	1.21	0.87 to 1.69
	34668	157	1.24	0.89 to 1.71



To:

Year	Cumulative patients	Cumulative events	RR	95%CI
2001	3772	6	1.70	0.29 to 9.99
	4814	10	0.78	0.22 to 2.79
	4934	11	0.97	0.28 to 3.36
	6173	14	1.10	0.37 to 3.24
2002	6684	17	0.77	0.29 to 2.04
	8284	19	0.92	0.37 to 2.31
	9348	30	1.24	0.58 to 2.64
	9942	30	1.23	0.57 to 2.63
	11066	38	1.42	0.72 to 2.83
2003	11474	38	1.42	0.72 to 2.83
	12625	41	1.34	0.70 to 2.58
2004	30869	145	1.23	0.88 to 1.72
	32553	149	1.19	0.85 to 1.66
	34104	152	1.17	0.84 to 1.62
	34362	157	1.14	0.82 to 1.57
	34668	165	1.13	0.82 to 1.54